MedPath

Alacrity Biosciences, Inc.

Alacrity Biosciences, Inc. logo
🇺🇸United States
Ownership
Private
Employees
1
Market Cap
-
Website
http://www.alacritybio.com

A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period

Phase 2
Completed
Conditions
Dry Eye
Interventions
Drug: placebo
First Posted Date
2007-02-23
Last Posted Date
2007-10-02
Lead Sponsor
Alacrity Biosciences, Inc.
Target Recruit Count
160
Registration Number
NCT00439400
Locations
🇺🇸

Ophthalmic Research Associates, Andover, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath